Abstract
Actinic keratosis is among the most commonly treated skin conditions in the outpatient setting. Its prevalence spans the globe, with greater distribution in fair skinned individuals and the immunocompromised. With high prevalence, increasing incidence and the risk of transformation to a cancerous lesion, prevention and timely treatment present opportunities to rein in costs.
The purpose of this article is to review published economic studies relating to the treatment of actinic keratosis, to summarize results discussing the cost drivers of current treatment modalities and to identify parameters most likely to influence the cost effectiveness of treatment.
We systematically conducted a published literature search for pharmacoeconomic research of actinic keratosis using title, abstract or full-text searches with the following search terms ([actinic OR solar] AND [keratosis OR keratoses]) AND (economic OR cost OR pharmacoeconomics OR decision). We included published articles referencing actinic keratosis in a standalone study or in a broader study referencing non-melanoma skin cancer and articles evaluating cost-of-illness, cost-of-treatment, cost minimization, cost effectiveness, cost utility, cost-benefit analysis and cost consequence.
Our review of the literature found nine studies devoted to pharmacoeconomic considerations of actinic keratosis treatments, with one article investigating both cost-of-illness and cost-of-treatment, two measuring cost-of-illness, two evaluating cost-of-treatment, one focusing on cost minimization, and three focusing on cost effectiveness. The literature compared a broad range of actinic keratosis treatments including topical medications, cryotherapy, photodynamic therapy, excision and a combination of treatment modalities. The direct cost of actinic keratosis management in the US was estimated at $US1.2 billion per year, with indirect costs totalling $US295 million (year 2004 values). The primary drivers of cost were physician office visits and associated procedures.
Pharmacoeconomic research defining standards, outcomes and areas of efficiencies in the treatment of actinic keratosis is in its infancy. To move towards more comprehensive analysis, research needs to focus on updating epidemiological data, evolving evidence-based standards, delineating cost drivers in immunocompetent and immunocompromised populations, and on health outcomes.
Similar content being viewed by others
References
Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000 Jan; 42 (1 Pt 2): 8–10
National Center for Health Statistics. National Ambulatory Health Care Survey (NAMCS), public use data files: 2008 [online]. Available from URL: ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets/NAMCS/ [Accessed 2008 Aug 15]
Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994 Oct; 131 (4): 455–64
Marks R, Ponsford MW, Selwood TS, et al. Non-melanotic skin cancer and solar keratoses in Victoria. Med J Aust 1983 Dec 10–24; 2 (12): 619–22
Green A, Beardmore G, Hart V, et al. Skin cancer in a Queensland population. J Am Acad Dermatol 1988 Dec; 19 (6): 1045–52
Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000 Aug; 115 (2): 273–7
Karagas MR, Zens MS, Nelson HH, et al. Measures of cumulative exposure from a standardized sun exposure history questionnaire: a comparison with histologic assessment of solar skin damage. Am J Epidemiol 2007 Mar 15; 165 (6): 719–26
Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988 Apr 9; 1 (8589): 795–7
Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991;127 (7): 1029–31
Chen GJ, Feldman SR, Williford PM, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg 2005 Jan; 31 (1): 43–7
Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003 Mar; 48 (3): 425–9
Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002 Apr; 146 Suppl. 61: 1–6
Green A. Changing patterns in incidence of non-melanoma skin cancer. Epithelial Cell Biol 1992 Jan; 1 (1): 47–51
Roberts WE. Dermatologic problems of older women. Dermatol Clin 2006 Apr; 24 (2): 271–80, viii
de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol 2007 Feb; 156 (2): 222–30
Helfand M, Gorman AK, Mahon S, et al. Actinic keratoses: final report. Agency for Healthcare Research and Quality; 2001 May 19. Report No.: contract 290–97-0018, task order no. 6 [online]. Available from URL: http://www.cms.hhs.gov/coverage/download/8b3-t3.pdf [Accessed 2009 Jun 28]
McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician 2007 Sep 1; 76 (5): 667–71
Gold MH. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses. J Drugs Dermatol 2008 Jan; 7 (1): 23–5
Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000 Jan; 42 (1 Pt 2): 25–8
Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006 Nov-Dec; 16 (6): 599–606
Agency for Healthcare Research and Quality, 2008 [online]. Available from URL: http://www.ahrq.gov/ [Accessed 2008 Jul 8]
American Academy of Dermatology, 2008 [online]. Available from URL: http://www.aad.org/ [Accessed 2008 Jul 8]
Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics 2004; 22 (2): 83–94
Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996 Aug 3; 313 (7052): 275–83
Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009 Jan; 1: 1–10. Epub ahead of print
The Society for Investigative Dermatology and The American Academy of Dermatology Association. The burden of skin diseases: 2005. Falls Church (VA): The Lewin Group, 2005 [online]. Available from URL: http://www.lewin.com/content/publications/april2005skindisease.pdf [Accessed 2008 Aug 25]
Warino L, Tusa M, Camacho F, et al. Frequency and cost of actinic keratosis treatment. Dermatol Surg 2006 Aug; 32 (8): 1045–9
Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002 Aug; 70 (2 Suppl.): 30–6
Streeton CL, Gospodarevskaya E, Harris AH. How are solar keratoses treated by general practitioners in Australia? Int J Dermatol 2006 Mar; 45 (3): 272–6
Caekelbergh K, Annemans L, Lambert J, et al. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006 Oct; 155 (4): 784–90
Annemans L, Caekelbergh K, Roelandts R, et al. Real-life practice study of the clinical outcome and cost-effectiveness of photodynamic therapy using methyl aminolevulinate (MAL-PDT) in the management of actinic keratosis and basal cell carcinoma. Eur J Dermatol 2008 Sep-Oct; 18 (5): 539–46
de Roos KP, Beljaards RC. The Delphi panel in the economic evaluation of photodynamic therapy for actinic keratosis and basal cell carcinoma: poor results? Br J Dermatol 2007 Jun; 156 (6): 1393–4
Caekelbergh K, Annemans L. Interest in interests in photodynamic therapy: reply from the authors [letter]. Br J Dermatol 2007 Jun; 156 (6): 1393
Weston A, Fitzgerald P. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 2004; 22 (18): 1195–208
Braathen LR, Szeimies R-M, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56 (1): 125–43
Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004 Sep; 43 (9): 638–42
American College of Physicians. Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 2008 Jun 17; 148 (12): 956–61
Tunis SR. Why Medicare has not established criteria for coverage decisions. N Engl J Med 2004 May 20; 350 (21): 2196–8
Ginsburg ME. Cost-effectiveness: will the public buy it or balk? Health Aff (Millwood) 2004 Jan-Jun; Suppl. Web Exclusives: W4–297-9
Ulrich C, Hackethal M, Ulrich M, et al. Treatment of multiple actinic keratoses with topical diclofenac 3% gel in organ transplant recipients: a series of six cases. Br J Dermatol 2007 May; 156 Suppl. 3: 40–2
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003 Apr 24; 348 (17): 1681–91
Ulrich C, Schmook T, Nindl I, et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol 2003 Nov; 149 Suppl. 66: 40–2
Palm MD, O’Donoghue MN. Update on photoprotection. Dermatol Ther 2007 Sep-Oct; 20 (5): 360–76
Heckman CJ, Coups EJ, Manne SL. Prevalence and correlates of indoor tanning among US adults. J Am Acad Dermatol 2008 May; 58 (5): 769–80
Moyal DD, Fourtanier AM. Broad-spectrum sunscreens provide better protection from solar ultraviolet-simulated radiation and natural sunlight-induced immunosuppression in human beings. J Am Acad Dermatol 2008 May; 58 (5 Suppl. 2): S149–54
Lim HW, Cooper K. The health impact of solar radiation and prevention strategies: report of the Environment Council, American Academy of Dermatology. J Am Acad Dermatol 1999 Jul; 41 (1): 81–99
Mettlin CJ. Skin cancer and ozone depletion: the case for global action. J Surg Oncol 2001 Jun; 77 (2): 76–8
Acknowledgements
We wish to thank Sudeep Karve, PhD, Ohio State University College of Pharmacy, for his assistance with 2005 NAMCS data. The Center for Dermatology Research is funded by a grant from Galderma Laboratories, L.P. Steven Feldman has received research, speaking and consultancy support from Galderma Laboratories, Graceway and Aventis. The remaining authors declare no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Neidecker, M.V., Davis-Ajami, M.L., Balkrishnan, R. et al. Pharmacoeconomic Considerations in Treating Actinic Keratosis. Pharmacoeconomics 27, 451–464 (2009). https://doi.org/10.2165/00019053-200927060-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200927060-00002